Trellis Bioscience

Trellis Bioscience is a private, pre-revenue biotech founded in 2018 that has developed the CellSpot™ platform for high-throughput discovery of native human monoclonal antibodies from healthy donors. The company's most advanced program, TRL1068, has demonstrated clinical proof-of-concept in a Phase 1 trial for reducing biofilm burden in prosthetic joint infections, a significant unmet medical need. Beyond infectious disease, Trellis has also discovered antibodies against immune checkpoint modulators and tumor-associated antigens for oncology, which are being advanced by partner Relevant Biosciences. The company is supported by non-dilutive funding from partnerships like CARB-X.

CellSpot™ platform for high-throughput discovery of native human monoclonal antibodies from memory B cells.

In biofilm-associated PJI, TRL1068 faces competition from novel antibiotics and phage therapies, but its unique antibody mechanism targeting biofilm structure is differentiated. In viral and oncology spaces, the competitive landscape is intense, with numerous large pharma and biotech companies developing monoclonal antibodies and other modalities.